On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which manufactured the antigen component of NVX-CoV2373, Novavax COVID-19 vaccine candidate.

Novavax increased its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX-CoV2373 was a stable, prefusion protein made using Novavax recombinant protein nanoparticle technology and includes Novavax proprietary Matrix-Mﾙ adjuvant.